Navigation Links
Data on VIVUS' QNEXA to be Presented in Six Posters at The Obesity Society's Annual Meeting
Date:10/7/2010

e not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission. CONTACT:   VIVUS, Inc.Investor Relations:Media Relations:Timothy E. MorrisThe Trout GroupGolinHarrisChief Financial Officer

Brian Korb

Susan Brophy650-934-5200

646-378-2923

sbrophy@golinharris.comBKorb@troutgroup.com

312-729-4359
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. ApoA-I Data Presented at European Society of Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... , , , , Efficiency of the standard protocols (1,2) ... (3) , , Propagate M13 ... For producing M13 ssDNA, mix 2.5 ml plating bacteria ... at 4 C for no more than 3 days) , ...
... , , , , Introduction ... , , , , , ... is an important part of your application. Many variables must be considered, , ... evaporation, and accessory chiller—so it's no surprise to find more , ...
... , To ensure that maximum transfection rates are achieved, the electroporation , ... , below for determining the ideal electroporation parameters as simply and , ... , Brochure available upon request., , , ... Field strength , ...
Cached Biology Technology:M13/Phagemid DNA Extraction Protocol 2Optimizing Büchi® Rotary Evaporator Applications 2Optimizing Büchi® Rotary Evaporator Applications 3Optimizing Büchi® Rotary Evaporator Applications 4Optimizing Büchi® Rotary Evaporator Applications 5Optimizing Büchi® Rotary Evaporator Applications 6Optimizing Büchi® Rotary Evaporator Applications 7Optimizing Büchi® Rotary Evaporator Applications 8
(Date:9/21/2014)... Contrary to what was previously thought, newborn immune T ... response to bacteria, according to a new study led ... very differently to that of adults, babies may still ... the study published in the journal Nature Medicine ... several different types of immune cells, including neutrophils which ...
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... of years has adapted to the arctic cold, and then ... dangerous for you. , This is happening to the small ... substance, called nonylphenol, comes from the use of certain detergents, ... endocrine disruptor, but when entering the worm it has another ... cells in its body from cold damage. , Enchytraeus ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... researchers at Kansas State,University, with collaboration from Epitopix ... against E. coli O157 in beef ... focus on the post-harvest food safety,aspect, whether it,s ... Thomson of,K-State,s College of Veterinary Medicine. Thomson is ...
... health research by providing a goldmine of stored human biological ... we make better use of these invaluable resources by collaborating ... theme of an international conference being held in March 2009. ... use of biobanks through harmonization? The conference ...
... at the Johns Hopkins Bloomberg School of Public Health ... that triggers an immune response in multiple mosquito species ... -the parasite that causes malaria in humans. By ... block the development of the malaria-causing parasite in ...
Cached Biology News:K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Harmonizing biobank research: An achievable world-wide goal 2Malaria immunity trigger found for multiple mosquito species 2